Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England.
Analysis of NHS data by Prostate Cancer UK found 50,751 men were diagnosed with prostate cancer in England in 2022 compared with 48,531 diagnoses of breast cancer. The figures increased again in ...